Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 155 publications
The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study.
Journal: BJU international
Published: June 10, 2026
NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 14, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.
Journal: Radiology
Published: March 31, 2026
Recruitment strategies in the PROMISE Registry: Evaluating institutional outreach, direct-to-patient marketing, and community engagement approaches in a decentralized germline genetic registry.
Journal: Contemporary clinical trials communications
Published: March 12, 2026
Clinical Trial Protocol for LPS-Boost: Intensified [177Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 08, 2026
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 26, 2026
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: February 11, 2026
Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.
Journal: JAMA network open
Published: January 16, 2026
Germline CDK12 variants in aggressive prostate cancer.
Journal: Cancer discovery
Published: January 14, 2026
Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.
Journal: Molecular cancer research : MCR
Published: January 14, 2026
A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Journal: The oncologist
Published: December 22, 2025
Last Updated: 09/26/2026